Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
1. Alpha Cognition's ALPHA-1062 shows promise for treating mild traumatic brain injury. 2. Preclinical data indicates reduction of toxic Tau forms linked to cognitive decline. 3. Study supported by US Department of Defense and Veterans Affairs personnel. 4. Next steps include formulation for sublingual administration and pharmacokinetic study. 5. ZUNVEYL is an FDA-approved treatment for Alzheimer's with potential synergy.